Safe Menopausal Relief through Hormone Therapy
This month will mark the fifteen-year anniversary of the halting of the 1991 Women’s Health Initiative (WHI), which sought to determine the safety, efficacy and additional benefits of synthetic hormone replacement therapy, not bioidentical. The journal, Climacteric, by the International Menopause Society publishes a series of articles offering conclusive evidence that the benefits of hormone replacement therapy (HRT) outweigh the risks.
In July of 2002, data from the WHI suggested that therapy using synthetic estrogen and progestin (synthetic progesterone) increased the risk of heart disease, stroke and breast cancer in women compared with those taking a placebo. The study was promptly halted, leaving a lingering dark cloud over hormone replacement therapy. Millions of women have been left without hope for relief from the symptoms of menopause.
Over the course of the last ten years, large scale analyses and comparative research has found that the risks observed in the WHI study pertained primarily to women who began HRT after menopause and, in fact, the majority of women in the HRT study were twelve years past menopause when treatment began. The articles in the journal reveal a series of conclusive findings that HRT benefits exceed the risks, including lowering the risk of heart disease, stroke, colorectal cancer, breast cancer and improving bone density.